echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Announcement of latest persistence and booster data for Clover's new coronary pneumonia adjuvanted protein vaccine

    Announcement of latest persistence and booster data for Clover's new coronary pneumonia adjuvanted protein vaccine

    • Last Update: 2022-05-18
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Article source: Medical Cube Info

    On April 18, Clover announced the company's adjuvant protein vaccine SCB-2019 (CpG 1018/aluminum adjuvant) at the 2022 World Vaccine Congress Washington 2022.
    More positive data from an ongoing evaluation study derived from an expanded dataset of more than 100 subjects

    .

    Clover Bio's new crown vaccine candidate consists of SCB-2019 antigen combined with two adjuvants, namely Dynavax's CpG 1018 adjuvant and aluminum hydroxide (aluminum adjuvant)
    .
    The SCB-2019 antigen is a stable trimeric structural fusion protein (S-trimer™) based on the S protein of the original strain of SARS-CoV-2 (new coronavirus)

    .

    A new dataset from an extended follow-up analysis confirms earlier findings and shows high and durable protection in individuals approximately 6 months after basal immunization with SCB-2019 (CpG 1018/aluminum adjuvant)
    .
    Follow-up analyses involved more than 14,700 subjects with no evidence of exposure to the new coronavirus and more than 14,700 subjects with evidence of previous exposure to the new coronavirus

    .

    Durability of protective efficacy for approximately 6 months after primary immunization

    Durability of protective efficacy for approximately 6 months after primary immunization

    About 6 months after primary immunization, in adults (18-59 years old) without a history of 2019-nCoV infection, the protective efficacy against severe illness remained 100% and the protective efficacy against hospitalization was 95%
    .
    In older adults (60 years and older), protection against severe illness remained 100% protective, and protection against hospitalization remained 100%

    .

    In individuals previously infected with 2019-nCoV, the protective efficacy against 2019-nCoV of any severity caused by any 2019-nCoV strain was 71% after primary immunization, and no clinical evidence of 2019-nCoV infection was observed over a period of approximately 6 months A trend of decreasing efficacy
    .
    After the first dose of SCB-2019 (CpG 1018/aluminum adjuvant) in this population, a rapid increase in neutralizing antibodies was associated with clinical protection against 2019-nCoV, which lasted for about 6 days after basic immunization.
    month

    .

    Up-to-date heterologous booster needle data in the extended dataset

    Up-to-date heterologous booster needle data in the extended dataset

    Among individuals previously vaccinated with two doses of AstraZeneca's Covid-19 vaccine, the heterologous booster vaccinated with SCB-2019 (CpG 1018/aluminum adjuvant) induced higher levels of neutralizing antibodies against the prototype strain than those vaccinated with three doses of AstraZeneca vaccine.
    Individuals are about 4 times higher

    .
    Compared with preliminary data of 76 people announced in February 2022, in the expanded 103 people, vaccination with SCB-2019 (CpG 1018/aluminum adjuvant) heterologous booster strongly activated immune response memory, providing immune maturation.
    evidence

    .

    In individuals previously vaccinated with two doses of AstraZeneca's new crown vaccine, the level of neutralizing antibody induced by the heterologous booster shot with SCB-2019 (CpG 1018/aluminum adjuvant) was higher than that of the three doses of AstraZeneca Individuals with the Likang vaccine were about 3 times higher
    .
    Compared with preliminary data published in March 2022 for 79 people, in the expanded 120 people, the SCB-2019 (CpG 1018/aluminum adjuvant) booster shot showed a significant improvement in beta compared with three doses of AstraZeneca vaccine.
    , Gamma, Delta, and Omicron were notable variants with stronger neutralizing antibody responses

    .

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.